Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

Panupong Hansrivijit 1*, Wisit Cheungpasitporn 2, Charat Thongprayoon 3 and Nasrollah Ghahramani 4

Abstract

**Background:** Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD.

**Methods:** Ovid MEDLINE, SCOPUS, and Cochrane Database of Systematic Reviews were searched up to September 2019. Out of 699 studies, we included 16 studies describing the treatment outcomes of rituximab in adult patients with FSGS or MCD. Results were reported in remission rate and relapse rate. Serious adverse events were also reported.

**Results:** A total of 16 studies were included in our review and analysis. All studies were observational studies and included a total of 221 patients (23.1% FSGS, 76.9% MCD). Mean follow-up duration was 26.3 ± 12.8 months. From the analysis of five studies with FSGS patients (n = 51), the overall remission rate and relapse rate of RTX therapy was 53.6% (95% CI, 15.8–87.6%) and 47.3% (95% CI, 25.4–70.2%), respectively. Complete remission occurred in 42.9%. In contrast, from the analysis of 11 studies with MCD patients (n = 170), the overall remission rate and relapse rate of RTX therapy was 80.3% (95% CI, 68.5–88.5%) and 35.9% (95% CI, 25.1–48.4), respectively. Complete remission occurred in 74.7%. Subgroup analyses showed that overall remission and relapse were not different after adjusted for study year and RTX dose for both FSGS and MCD. Incidence of serious adverse events was 0.092 events/year.

**Conclusions:** Rituximab may be considered as an additional treatment to the standard therapy for adult patients with FSGS and MCD. Remissions and relapses are similar between FSGS and MCD. Serious adverse effects of rituximab were uncommon. We encourage further randomized controlled trials to confirm the efficacy of rituximab therapy in these patients.

**Keywords:** Rituximab, FSGS, Focal segmental glomerulosclerosis, MCD, Minimal change disease, Nephrotic syndrome

* Correspondence: hansrivijitp@upmc.edu
1 Department of Internal Medicine, University of Pittsburgh Medical Center
Pinnacle, 504 S. Front St, Suite 3C, Harrisburg, PA 17104, USA

Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are common causes of nephrotic syndrome in adults. Although MCD is more common in children, its incidence in adults is up to 15% [1]. Similar to FSGS, adult-onset MCD may have severe clinical features and could potentially lead to end-stage kidney disease (ESKD), which is unusual for children-onset MCD [2]. Clinical presentations and steroid responsiveness of FSGS depend on the histological classification. Up to 63% of patients with primary FSGS have been reported to achieve remission after being treated with steroids [3]. The response rate of MCD to steroids was reported to be 75% [2]. However, relapses are common in both FSGS and MCD. Approximately 50% of patients with FSGS would experience at least one relapse [4]. In adults with MCD, relapses are frequent, occurring in 56–76% of cases [1, 2].

Long-term steroid therapy results in adverse clinical effects, such as dyslipidaemia, impaired fasting glucose, decreased bone mineralization, hypertension, and increased cardiovascular events. The aim of minimisation of the steroids can be achieved by adding alternative immunosuppressive agents. Several medications are considered second and third line treatment for resistant MCD or FSGS. Cyclosporine A, mycophenolate mofetil, azathioprine, tacrolimus, levamisole, cyclophosphamide and chlorambucil are most commonly used. Although, the efficacy of these medications is acceptable, their associated adverse events and toxicities would limit their use in long-term maintenance therapy.

Rituximab (RTX) is a chimeric monoclonal antibody which specifically binds to CD20-positive lymphocytes. For MCD and FSGS, the role for RTX has been well described in paediatric population. The remission rate of children with nephrotic syndromes was 44–80% in the literature [5–7]. Kronbichler et al. conducted a systematic review of RTX therapy for relapsing MCD and FSGS and found that RTX might be effective in reducing the number of relapses and sparing immunosuppressive agents [8]. In this study, treatment with RTX reduced the number of relapses per year from 1.3 to 0 relapse after therapy. Furthermore, RTX significantly reduced the severity of proteinuria and increased serum albumin level. However, remission rate was not reported in this study. Whether the efficacy of RTX remains similar in adult patients with MCD or FSGS is unknown.

To date, the remission rate of RTX therapy in adult patients with MCD or FSGS remains undetermined. Thus, we conducted a systematic review and meta-analysis to evaluate the response of RTX therapy in patients with treatment-resistant as well as treatment-naïve FSGS and MCD. We report the remission rate, and relapse rate following RTX therapy and its correlation with RTX dose.

Methods

Information sources and search strategy

The protocol for this systematic review and meta-analysis is under registration process with International Prospective Register of Systematic Reviews. The manuscript of this systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [9]. Ovid MEDLINE, SCOPUS, and the Cochrane Database were searched from the inception through September 2019. Two authors (P.H. and N.G.) performed a systematic search independently with the following search terms: “focal segmental glomerulosclerosis” OR “minimal change disease” AND “rituximab”. A manual search for related additional articles through the references of the included studies was performed. Additional details regarding the search strategy utilised for each database is provided in Supplemental Document 1.

Study selection

Only articles available in English were included for further screening. Studies were included in this systematic review if they were clinical trials, or observational studies that enrolled patients age ≥18 years with FSGS and MCD who were treated with rituximab therapy. Case reports and studies containing mixed paediatric and adult population without subgroup analysis were excluded. Studies containing patients with prior history of kidney transplantation were excluded. Eligible studies needed to provide the following outcomes: remissions, relapses, degree of proteinuria and serum creatinine [2]. Studies primarily reported other treatment outcomes or comprised of mixed FSGS, MCD and membranous nephropathy without subgroup analyses for FSGS or MCD alone were excluded. A complete remission was defined as proteinuria ≤300 mg/day. Partial remission was defined by a decrease of the initial urinary protein loss by 50% and ≤3.5 g/day. Retrieved articles were independently examined for eligibility by the two authors (P.H. and N.G.). Conflicts were resolved by consensus between all authors. All references were managed through Endnote X9.3 software (Clarivate Analytics, Philadelphia, PA, USA).

Data collection process

A data collecting form was invented to gather the following data from each included study: study title, name of authors, publication year, country where the study was conducted, type of study, patients’ diagnosis (FSGS or MCD or both), sample size, intervention (rituximab), total dosage of rituximab, treatment outcomes, follow-
up duration, CD19/20 depletion rate, and serious adverse events. Risk of bias was assessed using ROBINS-I tool for non-randomized studies of interventions [10]. Quality of studies fulfilled inclusion criteria was rated as low-, moderate- or high-risk of bias.

**Serious adverse events**
Using U.S. Food and Drug Administration (FDA) guidelines, serious adverse events are defined as adverse events associated with treatment which lead to 1) death, 2) life threatening condition, 3) prolonged hospitalisation or 4) permanent disability or damage disrupting the quality of life [11]. In this study, the number of serious adverse event were reported.

**Sensitivity analysis, subgroup analysis and publication bias**
To minimise inter-study heterogeneity, sensitivity analyses and subgroup analyses were performed. Sensitivity analyses were conducted by removing one study at a time. Subgroup analyses were preformed based on RTX dosage (< 1500 mg/m² vs. ≥ 1500 mg/m²), and literature date (prior to 2015 vs. after 2015). Presence of publication bias was evaluated by Egger's regression intercept and the Funnel plot. The latter method will be used if included number of studies is greater than 10 [12].

**Statistical analysis**
We used the Comprehensive Meta-Analysis software version 3.3.070 (Biostat Inc., NJ, USA) to conduct the meta-analysis and SPSS version 23.0 (IBM Corp., Armonk, NY, USA) for descriptive analyses. We applied a random-effects model to pool outcomes of interest including the remission rate and relapse rate of FSGS or MCD following rituximab therapy to minimise between-study variances. In addition, to compare the overall remission rate and relapse rate between FSGS and MCD patients, a subgroup analysis separating the two populations must be performed. Statistical heterogeneity of studies was assessed by the Cochran's Q test and the I² statistic (≥ 75%, high heterogeneity; 51–75%, moderate heterogeneity; 26–50%, low heterogeneity; ≤ 25%, insignificant heterogeneity) [13]. The correlations between variants were analysed by Pearson's correlation. Continuous data obtained from descriptive analysis were presented in mean ± standard deviation (SD) or median ± interquartile range (IQR), depending on data distribution. P-value less than 0.05 is considered statistically significant.

**Results**

**Study characteristics**
A total of 699 potential eligible articles were identified from our literature search. The flowchart of systematic literature review is illustrated in Fig. 1. A total of 16 studies were included in our systematic review and a total of 14 studies were included in our meta-analyses. All included studies were observational studies. Twelve of 16 were in prospective and four of them were in retrospective design. The studies included a total of 221 patients. Fifty-one patients (23.1%) had FSGS as their primary disease while 170 patients (76.9%) had MCD. The study characteristics are demonstrated in Table 1.

| Study characteristics | FSGS | MCD |
|-----------------------|------|-----|
| Total patients        | 51   | 170 |
| FSGS patients         | 51   |     |
| MCD patients          | 170  |     |
| RituXmab dose (mg/m²)  |      |     |
| Low dose              |      |     |
| High dose             |      |     |

**Remissions and relapse of FSGS**
We excluded Ruggenenti et al. [22] from meta-analysis of overall remission as this study included patients who were already in remission. Likewise, Sugiura et al. [16] was excluded as they included mixed population of patients in remission and those who were not. A total of 51 patients from five studies were identified. By using random-effects model of meta-analysis, we found that the overall remission of FSGS following RTX therapy was 53.6% (95% CI, 15.8–87.6%; I² = 74.4%; Fig. 2a). Complete remission was 42.9% (95% CI, 10.8–82.3%; I² = 72.2%) and partial remission was 10.7% (95% CI, 7.0–59.2%; I² = 59.3%). Mean follow-up duration among FSGS patients was 18.7 ± 9.0 months. The relapse rate of FSGS in patients who were treated with rituximab was 47.3% (95% CI, 25.4–70.2%; I² = 35.4%; Fig. 2b). These results remained statistically significant on sensitivity analyses.

In addition, we performed a subgroup analysis of FSGS remission and relapse based on study year (prior to 2015 versus 2015 and after) and RTX dosing. We defined low-dose RTX as < 1500 mg/m², and high-dose RTX as ≥ 1500 mg/m² of total RTX received. There was no significant difference in remission or relapse after adjusted for RTX dosing and study year. Table 2 demonstrates subgroup analyses of FSGS patients treated with RTX therapy.

**Remissions and relapse of MCD**
Eleven studies of MCD patients (n = 170) remained in the analysis after exclusion of studies containing FSGS patients. The overall remission rate was 80.3% after RTX therapy (95% CI, 68.5–88.5%; I² = 46.4%). This is illustrated in Fig. 2c. We found that the complete remission rate in MCD patients was 74.7% (95% CI, 62.5–84.0%;
I² = 15.5%) while partial remission was 5.6% (95% CI, 9.9–24.8%; I² = 0%). With a mean follow-up duration of 27.6 ± 13.5 months, relapse occurred in 35.9% (95% CI, 25.1–48.4%; I² = 46.8%; Fig. 2d) of MCD patients who achieved remission following RTX therapy. The results remained significant on sensitivity analyses.

For subgroup analysis, we found no significant difference in remission or relapse after adjusted for study year (prior to 2015 versus 2015 and after) and RTX dosing (< 1500 mg/m² versus ≥1500 mg/m²) (Table 2).

Subgroup analysis of remission and relapse between FSGS and MCD

We performed a subgroup analysis comparing the overall remission and relapse between patients with FSGS and patients with MCD. The mean follow-up duration was 26.3 ± 12.8 months. Although the overall remission rate of MCD patients was higher than those with FSGS, the difference did not reach statistical significance (80.3% for MCD and 53.6% for FSGS; Q-value = 1.661; p = 0.678). Likewise, a subgroup analysis on the relapse rate between FSGS and MCD patients showed no statistical significance (47.3% for FSGS and 35.9% for MCD; Q-value = 0.705; p = 0.401).

Reported adverse events

From all 16 studies, rituximab is well tolerated. Serious adverse events were reported in only six studies. Serious side effects include cutaneous eruption/type 1 hypersensitivity/fixed drug eruption, infusion reaction, leukopae- nia, and pneumonia. By analysing all 16 studies, using random-effects model, the incidence of serious adverse events was 0.092 events per year (95% CI, 0.056–0.148; I² = 0%). There was a positive correlation between RTX dose and severe adverse events rate (r² = 0.187; p = 0.03).

Evaluation for publication Bias

Publication bias was evaluated by the Funnel plot of standard error as well as Egger’s regression intercept. Here, we reported the Funnel plot and Egger’s test on both overall remission and relapse. The Funnel plots for publications reporting remission and relapse of pooled FSGS and MCD were illustrated in Fig. 3. Egger’s regression intercept for overall remission and for disease relapse did not suggest possibility of publication bias (p =
| Study                          | Year | Country | Type of Study | Patients | Intervention | Mean RTX Dose (mg/m² median ± IQR) | Outcomes | CD19/20 Depletion Rate | Study Follow-up Time | Serious Adverse Events |
|-------------------------------|------|---------|---------------|----------|--------------|-----------------------------------|-----------|------------------------|----------------------|-----------------------|
| Fernandez-Fresnedo et al. [14] | 2009 | Spain   | Observational (prospective) | SR FSGS 8 | RTX          | 1500                              | SCR: 1.4 ± 0.5 (pre) vs. 2.2 ± 1.8 (post) Proteinuria: 140 ± 44 (pre) vs. 10.5 ± 4.9 (post) Remission: 0% (CR 0%, PR 0%) | CD20 depleted 100% | 164 ± 5.1 mo           | None                 |
| Hoxha et al. [15]             | 2011 | Germany | Observational (prospective) | FR and SD MCD 6 | RTX          | 375                              | CR: 5/6 (83.3%) PR: 1/6 (16.7%) Relapse (17.2 ± 4.8 mo): 3/6 (50%) – all were successfully treated with rituximab | B-cell depleted 100% | 172 ± 4.8 mo           | None                 |
| Sugiura et al. [16]           | 2011 | Japan   | Observational (prospective) | SD MCD and FSGS 14 (10, MCD; 4, FSGS) | RTX          | 375                              | MCD – Proteinuria*: 38 ± 4 (pre) vs. 0.4 ± 1.2 (post) MCD – SCR: 0.7 ± 0.2 (pre) vs. 0.7 ± 0.2 (post) FSGS – Proteinuria*: 5.2 ± 24 (pre) vs. 23 ± 28 (post) FSGS – SCR: 11 ± 0.6 (pre) vs. 1.0 ± 0.5 (post) Follow-up time 6 months | B-cell depleted 100% | 6 mo                  | Cutaneous eruption (7.1%) |
| Kong et al. [17]              | 2013 | Australia | Observational (retrospective) | MCD and FSGS with other current treatment 11 (7, MCD; 4, FSGS) | RTX          | 600 ± 900 mg total [FSGS 600 ± 725; MCD 600 ± 1500] | Complete remission: total 7/11 (63.6%), MCD 5/7 (71.4%), FSGS 2/4 (60%) Partial remission: total 3/11 (27.2%), MCD 2/7 (28.6%), FSGS 1/4 (25%) No response: 1/11 (9.1%) Relapse: total 3/11 (27.2%), MCD 2/7 (28.6%), FSGS 0% Follow-up time 6 months | N/A                   | 265 ± 16 mo [19 mo (13–43) for MCD and 29 mo (11.8–49.3) for FSGS] | Infusion reaction (33.3%) Pneumonia (4.2%) |
| Munyentwali et al. [18]       | 2013 | France  | Observational (prospective) | FR or SD MCD 17 | RTX          | 1125 ± 750                        | Remission: 11/17 (64.7%) Relapse: 6/17 (35.3%), only 4/6 (66.7%) of relapsed patients achieved remission at last follow-up Mean follow-up: 295 ± 182 months | N/A                   | 295 mo (5.1–82)        | None                 |
| Takei et al. [19]             | 2013 | Japan   | Observational (prospective) | SD MCNS 25 | RTX          | 375                              | Remission: 22/25 (88%) Relapse: 3/25 (12%) Follow-up time 12 months | B-cell depleted 100% | 12 mo                 | Fixed drug eruption (4%) Leukopenia (4%) |
| Bruchfeld et al. [20]         | 2014 | Sweden  | Observational (prospective) | GC-dependent or GC-resistant MCD 16 | RTX          | 1250 ± 1300 (median ± IQR)            | Complete remission: 13/16 (81.3%) Partial remission: 2/16 (12.5%) Relapse at 28 months: 7/16 (43.8%) | B-cell depleted 100% | 44 ± 43 mo             | None                 |
| Guitard et al. [21]           | 2014 | France  | Observational (retrospective) | MCNS with other 41 | RTX + conventional | 2000 ± 500 (median ± IQR)            | Complete remission: 25/41 (61.0%) | B-cell depleted 100% | 44 (6–82) mo          | None                 |
| Study                        | Year | Country | Type of Study | Patients | Number | Intervention | Mean RTX Dose (mg/m²) (median ± IQR) | Outcomes | CD19/20 Depletion Rate | Study Follow-up Time | Serious Adverse Events |
|-----------------------------|------|---------|---------------|----------|--------|--------------|-------------------------------------|-----------|------------------------|----------------------|-----------------------|
| Ruggenenti et al. [22]      | 2014 | Italy   | Observational (prospective) | FR or SD FSGS in remission | 8      | RTX          | 375                                 | Partial remission: 7/41 (17.1%) Relapse at median time of 18 months: 18/32 (56.2%) | 100% | B-cell depleted 100% | 12 mo                | None                  |
| Papakrivopoulou et al. [23] | 2016 | UK      | Observational (prospective) | FR or SD MCD | 15     | RTX          | 2000 ± 1000 (median ± IQR)          | Remission: 10/15 (66.7%) Relapse: 5/15 (33.3%) Median steroid free survival after RTX was 25 months (range 4–34) Mean relapse frequency decreased from 2.60 ± 0.28 to 0.4 ± 0.19 * | B-cell depleted 100% | 20 ± 14 mo | Type 1 hypersensitivity (46%) |
| King et al. [24]            | 2017 | UK      | Observational (prospective) | FR MCD | 13     | RTX          | 2000 mg total                      | Remission: 6/13 (46.2%) Relapse at 20 mo: 7/13 (53.8%). All patients were in remission following subsequent rituximab Median number of relapses was reduced from 4 to 0.4 episodes/year | N/A | 20 mo (6–85) | None                  |
| Ren et al. [25]             | 2017 | China   | Observational (prospective) | SD or SR MCD or FSGS | 15 (9, MCD; 6, FSGS) | RTX | 1500          | Complete remission: 13/15 (86.7%) Partial remission: 2/15 (13.3%) Relapse at 10 months: 2/15 (13.3%) All relapsed cases achieved CR by month 12 | B-cell depleted 100% | 8 mo (3–36) | None                  |
| Roccatello et al. [26]      | 2017 | Italy   | Observational (prospective) | Treatment-naive FSGS | 8      | RTX          | 3000                                 | Proteinuria: mean 5.1 ± 1.9 g/24 h (pre) vs. 3.8 ± 1.8 (post) SCR: mean 2.4 ± 1.2 mg/dL (pre) vs. 3.2 ± 2.5 (post) PR: 1/8 (12.9%) CR: 0/8 (0%) Follow-up time 18 months | N/A | 29.1 ± 88 mo | None                  |
| Cortazar et al. [27]        | 2018 | USA     | Observation (prospective) | FR, SD or SR MCD and FSGS | 20 (13, MCD; 7, FSGS) | RTX for continuous B-cell depletion | 3375 ± 750 mg total (MCD 3375 ± 16875; FSGS 3000 ± 1875) | Complete remission: 11/13 (84.6%, MCD) and 1/7 (14.3%, FSGS) Partial remission: 2/13 (15.4%, MCD) and 6/7 (85.7%, FSGS) Relapse at 3 years: None for MCD and 4/7 (57.1%, FSGS) | B-cell depleted 100% | 35 mo (range 19, 57; IQR 33.75) | Serious infection 0.04 infections per year (95% CI 0.012–0.12) Serious adverse events 0.10 events per year (95% CI |
| Study | Year | Country | Type of Study | Patients | Intervention | Mean RTX Dose (mg/m² median ± IQR) | CD19/20 Depletion rate | Outcomes | Study Follow-up Time | Serious Adverse Events |
|-------|------|---------|---------------|----------|--------------|-----------------------------------|-------------------------|-----------|---------------------|----------------------|
| Fenoglio et al. [28] | 2018 | Italy | Observational (retrospective) Treatment naïve | MCD | RTX | 1500 | CD19: 1.55 ± 1.18 (pre) vs. 0.62 ± 0.66 (post) | CR: 5/6 (83.3%) | Proteinuria*: 11.75 ± 8.50 (pre) vs. 0.28 ± 0.50 (post) | 21.5 mo (8–36) | None |
| Ramachandran et al. [29] | 2019 | India | Observational (prospective) CNI-dependent | MCD/FSGS | RTX for persistent B-cell depletion | 791.66 ± 131.60 mg total (range 600–1100) | CR: 62.5% (7/12) | Remission at 12 mo was 79.16% (CR 62.5%, PR 25%) and at last visit (mean 30.58 ± 9.24 mo) MCD: CR 100% at 12 mo; 3/11 (27.3%) relapsed FSGS: CR 53.84% (7/13) and PR 15.38% (2/13) at last visit. | 30.58 ± 9.24 mo | None |

* Statistical significant. Abbreviations: CNI, calcineurin inhibitors; CR, complete remission; PR, partial remission; RTX, rituximab; SD, steroid dependent; SR, steroid resistant; UPCR, urine protein/creatinine ratio.
0.575 and \( p = 0.511 \) for overall remission and relapse, respectively).

**Discussion**

Our results suggest that rituximab may be considered as an additional treatment for FSGS and preferably MCD in adults. In this study, we reported that 53.6% of FSGS patients achieved remission as compared to 80.3% in MCD patients. With a mean follow-up of at least two years, up to 47.3% of FSGS patients and 35.9% of MCD patients relapsed. However, although FSGS patients had lower overall remission rate with slightly higher relapses in comparison to MCD patients, these differences were not statistically significant because there was significant variance within each group. Audience should be cautious when interpret this finding as there was no direct comparison to the standard treatment or concomitant therapy. Furthermore, the results maybe underpowered given smaller sample size in FSGS group. In addition, the burden of nephrotic syndrome at the time of treatment with rituximab was not universal across studies. It is possible that patients with mild disease would respond better to rituximab therapy. Randomized controlled studies are required to increase the power of the analysis and to distinguish the efficacy of rituximab therapy in FSGS and MCD patients in comparison with the standard treatment.

As a reference, the response of treatment-naïve FSGS and MCD to steroids was reported to be 63 and 75% in the literature, respectively [2, 3]. At least 50% of patients with FSGS or MCD would experience relapses through the course of standard treatment [1, 2, 4]. In this study, we also found that the remission rate and relapse rate remained constant over time. However, it is also worth noting that our reported relapse rate might be underreported as relapses can increase if patients are followed for a longer period of time. One single-centre prospective study has demonstrated that among patients diagnosed with frequently relapsing or treatment-resistant MCD and FSGS, younger age at diagnosis was significantly associated with increased incidence of disease relapse after rituximab therapy [22].

It remains unclear how rituximab leads to remission in patients with FSGS and MCD. Rituximab is a monoclonal antibody directed against CD20-positive lymphocytes. The use of rituximab has been approved by the
U.S. FDA for B-cell-mediated malignancies and connective tissue diseases. Infiltration of lymphocytes has been described in transplanted kidneys affected by FSGS recurrence [30] which suggested that FSGS is an antibody-mediated disease. However, the actual pathogenesis of FSGS remains undiscovered. Rituximab was shown to play roles in B-cell-independent mechanisms as well. For instance, rituximab was demonstrated to regulate the activity of acid-sphingomyelinase (ASMase), which are essential for signalling molecules on the podocytes [31, 32]. Perosa et al. reported that rituximab might cross react with sphingomyelin-phosphodiesterase-acid-like-3b (SMPDL-3b) [33]. Reduction in SMPDL-3b-positive podocytes was observed in biopsies showing FSGS [34]. Rather than acting on antibody production directly, rituximab might prevent actin cytoskeleton remodelling in the podocytes by preserving sphingolipid-related enzymes and SMPDL-3b and ASMase activity. Further basic science researches are needed to determine the role of rituximab in the glomerular level.

We have also shown that rituximab was well tolerated in all studies with the incidence of serious adverse events of 0.092 events per year. Administering higher dose of rituximab was associated with higher adverse events. This finding is similar to what previously described in chronic lymphocytic leukaemia (CLL). Patients with CLL are usually treated with high dose rituximab, thus, the incidence of adverse events is higher [35]. Although there are literatures suggesting that relapse usually occurred in the setting of B-cell recovery [18, 23], the role of B-cell depletion-targeted RTX therapy to prevent relapse, however, requires further investigations using randomized controlled trials.

To the best of our knowledge, this is the first meta-analysis describing the treatment outcomes of rituximab therapy for FSGS and MCD in adults. However, our study has some limitations. First, all included studies were observational studies making it is difficult to conclude if rituximab is more effective than the standard

| Subgroup analyses of included studies | N | Event, % | 95% CI |
|--------------------------------------|---|----------|--------|
| **FSGS**                             |   |          |        |
| Remission                            |   |          |        |
| RTX < 1500 mg/m²                     | 2 | 78.5     | 59.7–90.0 |
| RTX ≥ 1500 mg/m²                     | 3 | 48.4     | 4.0–99.5 |
| Prior to 2015                         | 2 | 31.7     | 10.0–95.6 |
| 2015 and later                        | 3 | 65.3     | 14.7–95.4 |
| Relapse                              |   |          |        |
| RTX < 1500 mg/m²                     | 3 | 45.3     | 18.1–75.6 |
| RTX ≥ 1500 mg/m²                     | 1 | 57.1     | 23.0–85.6 |
| Prior to 2015                         | 2 | 31.8     | 15.0–55.2 |
| 2015 and later                        | 2 | 67.3     | 37.6–87.5 |
| **MCD**                              |   |          |        |
| Remission                            |   |          |        |
| RTX < 1500 mg/m²                     | 6 | 86.5     | 72.0–94.1 |
| RTX ≥ 1500 mg/m²                     | 5 | 73.4     | 53.2–87.1 |
| Prior to 2015                         | 6 | 81.6     | 70.2–89.3 |
| 2015 and later                        | 5 | 79.7     | 51.8–93.5 |
| Relapse                              |   |          |        |
| RTX < 1500 mg/m²                     | 6 | 31.3     | 20.7–44.4 |
| RTX ≥ 1500 mg/m²                     | 4 | 41.7     | 22.5–63.8 |
| Prior to 2015                         | 6 | 37.3     | 23.4–53.8 |
| 2015 and later                        | 4 | 32.2     | 15.6–55.1 |

Table 2 Subgroup analyses of included studies

Fig. 3 Funnel plots evaluating publication bias. a Funnel plot for publications reported the overall remission in patients with pooled FSGS and MCD. b Funnel plot for publications reported the relapses in patients with pooled FSGS and MCD.
treatments due to lack of comparisons and concomitant therapy. Second, most MCD patients included in our analyses were diagnosed based upon the initial biopsy. Whether these patients potentially progressed to FSGS on subsequent biopsies remains unknown. Third, the histological subtype of FSGS was not identified as this would impact the response to treatment as well. Fourth, only five studies were available for analysis of FSGS. More studies on adult patients with FSGS are needed. Finally, our study demonstrated moderate degree of heterogeneity with most I² ranging from 51 to 75%. However, we utilised random-effects and mixed-effects model along with sensitivity analyses to minimise the contamination from heterogeneity. Several clinical trials proving the efficacy of rituximab in treatment of FSGS and MCD are currently being undertaken including RIFIREINS and TURING study (NCT03970577, ISRCTN16948923, JPRN-UMIN000005231, JPRN-UMIN00019844, CTRI/2018/01/011316, EUCTR2017–003366-27-NL).

Conclusions
Rituximab may be considered as an additional treatment to the standard therapy for FSGS and MCD in adult patients. Remissions and relapses are similar between FSGS and MCD group. Serious adverse effects of rituximab were uncommon. We encourage further randomized controlled trials to confirm the efficacy of rituximab therapy in these patients.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12882-020-01797-7.

Additional file 1.

Abbreviations
RTX: Rituximab; FSGS: Focal segmental glomerulosclerosis; MCD: Minimal change disease; ESKD: End-stage kidney disease; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analysis; FDA: Food and Drug Administration

Acknowledgements
We would like to thank our Meta-analysis Statistician Team for consultation and advice. An abstract of this research was presented at the National Kidney Foundation Spring Clinical Meeting 2020.

Authors’ contributions
P.H. and N.G. created the protocol for this study. P.H. and W.C. searched for eligible literatures. P.H. and C.T. extracted the data. P.H. analysed the data and drafted the manuscript. P.H., W.C., C.T., and N.G. revised the manuscript for submission. The authors read and approved the final manuscript.

Funding
No funding reported for this study.

Availability of data and materials
The datasets generated and/or analysed during the current study are available in Table 1, Figs. 1, 2 and Supplemental Document 1.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
Charat Thongprayoon, MD is a member of the editorial board for BMC Nephrology journal. Other authors declared no conflict of interest.

Author details
1Department of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, 504 S. Front St, Suite 3C, Harrisburg, PA 17104, USA. 2Division of Nephrology, University of Mississippi Medical Center, Jackson, MS 35216, USA. 3Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA. 4Division of Nephrology, Department of Medicine, Penn State University College of Medicine, Hershey, PA 17033, USA.

Received: 5 December 2019 Accepted: 6 April 2020
Published online: 15 April 2020

References
1. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. 1986;29(8):1215–23.
2. Waldman M, Crew RJ, Valevski A, Busch J, Stokes B, Markowitz G, D’Agati V, Appel G. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–53.
3. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15(8):2169–77.
4. Troyanov S, Wall CA, Miller JA, Scholey MJ, Catran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061–8.
5. Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2013;28(2):257–64.
6. Kemper MJ, Gelferemann J, Habbig S, Kimar RT, Dittkens K, Jungnahlthay T, Pape L, Patzer L, Billing H, Weber L, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27(5):1910–5.
7. Prytula A, Iijima K, Kamei K, Geoay D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2010;25(3):461–8.
8. Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, Rudnicki M. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol. 2014;39(4):322–30.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
10. Steine JA, Hemman MA, Reeves BC, Savovic J, Berjamin ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Broutron J et al: ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. (1756–1833 (Electronic)).
11. U.S. Food and Drug Administration. What is a Serious Adverse Event? https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event. Accessed on 29 Feb 2020.
12. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in meta-analyses. BMJ. 2003;327(7414):557–60.
13. Fernandez-Fresnedo G, Segarra A, González E, Alexandre S, Delgado R, Ramos N, Egido JS, Piaga M. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4(8):1317–23.
14. Hoxha E, Stahl RAK, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol. 2011;76(2):151–8.
16. Sugiura H, Takei T, Itabashi M, Tsukada M, Moriya T, Kojima C, Shiohira T, Shimizu A, Tsuruta Y, Amemiya N, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011;117(2):c98–c105.

17. Kong WY, Swaminathan R, Irish A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol. 2013;45(3):795–802.

18. Munyentwali H, Bouchi K, Audard V, Remy P, Lang P, Mejaat R, Deschênes G, Ronco PM, Plaisier EM, Dahan KY. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83(3):S11–6.

19. Takei T, Itabashi M, Moriya T, Kojima C, Shiohira S, Shimizu A, Tsuruta Y, Ochi A, Amemiya N, Mochizuki T, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013;28(5):1225–32.

20. Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M. Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant. 2014;29(4):851–6.

21. Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, Guigonis V, Ducet F, Pesne C, Pinson Y, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. 2014;29(11):2084–91.

22. Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ené-Iordache B, Rudnicki M, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25(4):850–63.

23. Papakrivopoulou E, Shendi AM, Salama AD, Khosravi M, Connolly JO, Trompeter R. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal changedisease. Nephrology. 2016;21(10):893–900.

24. King C, Logan S, Smith SW, Hewins P. The efficacy of rituximab in adult frequently relapsing minimal change disease. Clin Kidney J. 2017;10(1):16–9.

25. Ren H, Lin L, Shen P, Li X, Xie J, Pan X, Zhang W, Chen N. Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis. Oncotarget. 2017;8(55):93438–43.

26. Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, Barreca A, Fenoglio R, Baldovino S, Menegatti E. High-dose rituximab ineffective for focal segmental Glomerulosclerosis: a long-term observation study. Am J Nephrol. 2017;46(2):108–113.

27. Cortazar FB, Rosenthal J, Laliberte K, Niles JL. Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome. Clin Kidney J. 2018;12(2):224–31.

28. Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, Menegatti E, Roccatello D. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. OncoTarget. 2018;9(48):28799–804.

29. Ramachandran R, Bharat I, Rao I, Kashif AW, Nada R, Minz R, Gupta KL, Kohli HS. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. Nephrology. 2019;24(12):1241–47.

30. de Oliveira JG, Xavier P, Carvalho E, Ramos JP, Magalhaes MC, Mendes AA, Faria V, Guerra LE. T lymphocyte subsets and cytokine production by graft-infiltrating cells in FSGS recurrence post-transplantation. Nephrol Dial Transplant. 1999;14(3):713–6.

31. Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Muller S, Jaffrezou JP, Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood. 2004;104(4):1166–73.

32. Bollinger CR, Teichgraber V, Gulbins E. Ceramide-enriched membrane domains. Biochim Biophys Acta. 2005;1746(3):284–94.

33. Perso F, Favone A, Caragno MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b in patients with chronic lymphocytic leukemia. Vnitr Lek. 2013;61(7–8):626–32.